+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06632977

Evaluation of Genetic Testing-Guided Targeted Treatments for Metastatic Castration-Resistant Prostate Cancer in the PREDICT Trial

Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03

474

Participants Needed

108

Research Sites

234 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the role of genetic testing in guiding targeted treatments for patients with castration-resistant prostate cancer that has spread. This phase II trial investigates whether assigning treatments based on DNA and RNA mutations found in cancer tissue can better control tumor growth. The study aims to measure tumor response, safety, progression-free survival, overall survival, and patient-reported outcomes among other clinical and molecular factors. Participants undergo genetic testing on previously collected tumor samples and are assigned to one of three treatment groups based on molecular tumor board decisions. Treatments include valemetostat tosylate taken orally daily in 28-day cycles carboplatin and cabazitaxel given intravenously every 21 days or physician-chosen regimens such as cabazitaxel alone, abiraterone acetate with prednisone orally, enzalutamide orally, or lutetium Lu 177 vipivotide tetraxetan intravenously every 42 days for up to six cycles. Throughout the trial, patients also receive regular MRI or CT scans, bone scans, and may opt for additional PET imaging and blood sample collections. During and after treatment, participants are closely monitored through imaging and laboratory tests to assess tumor response and side effects. After completing treatment, those without disease progression have follow-up visits every two months for six months, then every three months for up to five years. The study collects data on radiographic progression, survival, prostate-specific antigen changes, skeletal events, subsequent therapies, and adverse events. Patient experiences and molecular markers are also evaluated to understand treatment response and resistance.

CONDITIONS

Brief Title

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Research Team

R

Rana McKay, MD

S

Shiva Baghaie

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here